{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:58:51Z","timestamp":1759777131498},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,7,23]],"date-time":"2008-07-23T00:00:00Z","timestamp":1216771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00280-008-0803-x","type":"journal-article","created":{"date-parts":[[2008,7,22]],"date-time":"2008-07-22T02:25:31Z","timestamp":1216693531000},"page":"793-798","source":"Crossref","is-referenced-by-count":5,"title":["Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551"],"prefix":"10.1007","volume":"63","author":[{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Ratain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"For the Cancer and Leukemia Group B","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,23]]},"reference":[{"issue":"11","key":"803_CR1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1990.8.11.1907","volume":"8","author":"R Ohno","year":"1990","unstructured":"Ohno R, Okada K, Masaoka T et al (1990) An early Phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8(11):1907\u20131912","journal-title":"J Clin Oncol"},{"issue":"7","key":"803_CR2","first-page":"1047","volume":"21","author":"K Ota","year":"1994","unstructured":"Ota K, Ohna R, Shirakawa S et al (1994) Late Phase II study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematologic Malignancies. Japanese J Ca Chemoth 21(7):1047\u20131055 (Japanese)","journal-title":"Japanese J Ca Chemoth"},{"issue":"7 Suppl 8","key":"803_CR3","first-page":"53","volume":"15","author":"AH Sarris","year":"2001","unstructured":"Sarris AH, Romaguera J, Hagemeister FB et al (2001) Irinotecan in relapsed or refractory non-Hodgkins lymphoma. Oncology (Williston Park) 15(7 Suppl 8):53\u201356","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"803_CR4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1081\/CNV-120001143","volume":"20","author":"EH Kraut","year":"2002","unstructured":"Kraut EH, Balcerzak SP, Young D et al (2002) A phase II study of topotecan in non-Hodgkin\u2019s lymphoma: an Ohio State University phase 2 consortium study. Cancer Invest 20(8):174\u2013179","journal-title":"Cancer Invest"},{"issue":"7","key":"803_CR5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1023\/A:1011172215216","volume":"12","author":"A Younes","year":"2001","unstructured":"Younes A, Preti HA, Hagemeister FB et al (2001) Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol 12(7):923\u2013927","journal-title":"Ann Oncol"},{"key":"803_CR6","first-page":"6039","volume":"51","author":"AY Chen","year":"1991","unstructured":"Chen AY, Yu C, Potmesil M et al (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039\u20136044","journal-title":"Cancer Res"},{"key":"803_CR7","first-page":"4385","volume":"49","author":"YH Hsiang","year":"1989","unstructured":"Hsiang YH, Liu LF, Wall ME et al (1989) DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49:4385\u20134389","journal-title":"Cancer Res"},{"issue":"14","key":"803_CR8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2165\/00003495-200262140-00004","volume":"62","author":"H Ulukan","year":"2002","unstructured":"Ulukan H, Swaan PW (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs 62(14):2039\u20132057","journal-title":"Drugs"},{"issue":"4","key":"803_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00280-003-0657-1","volume":"52","author":"J Leguizamo","year":"2003","unstructured":"Leguizamo J, Quinn M, Takimoto CH et al (2003) A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer Chemother Pharmacol 52(4):333\u2013338","journal-title":"Cancer Chemother Pharmacol"},{"key":"803_CR10","first-page":"269","volume":"1","author":"E Rubin","year":"1995","unstructured":"Rubin E, Wood V, Bharti A et al (1995) A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Canc Res 1:269\u2013276","journal-title":"Clin Canc Res"},{"issue":"4","key":"803_CR11","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.1996.14.4.1236","volume":"14","author":"W Dahut","year":"1996","unstructured":"Dahut W, Harold N, Takimoto C et al (1996) Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14(4):1236\u20131244","journal-title":"J Clin Oncol"},{"issue":"2","key":"803_CR12","first-page":"317","volume":"4","author":"JP Eder","year":"1998","unstructured":"Eder JP, Supko JG, Lynch T et al (1998) Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Canc Res 4(2):317\u2013324","journal-title":"Clin Canc Res"},{"issue":"7","key":"803_CR13","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.1998.16.7.2345","volume":"16","author":"WH Wilson","year":"1998","unstructured":"Wilson WH, Little R, Pearson D et al (1998) Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. J Clin Oncol 16(7):2345\u20132351","journal-title":"J Clin Oncol"},{"key":"803_CR14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0378-4347(94)00051-4","volume":"655","author":"CH Takimoto","year":"1994","unstructured":"Takimoto CH, Klecker RW, Dahut WL et al (1994) Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid phase extraction and high performance liquid chromatography. J Chromatogr B Biomed Appl 655:97\u2013104","journal-title":"J Chromatogr B Biomed Appl"},{"key":"803_CR15","first-page":"1325","volume":"5","author":"H Minami","year":"1999","unstructured":"Minami H, Lad TE, Nicholas MK et al (1999) Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72\u00a0hours in Phase II studies. Clin Cancer Res 5:1325\u20131330","journal-title":"Clin Cancer Res"},{"key":"803_CR16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002800050825","volume":"42","author":"JP Eder","year":"1998","unstructured":"Eder JP, Chan V, Wong J et al (1998) Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 42:327\u2013335","journal-title":"Cancer Chemother Pharmacol"},{"key":"803_CR17","first-page":"1425","volume":"57","author":"CM Whitacre","year":"1997","unstructured":"Whitacre CM, Zborowska E, Gordon NH et al (1997) Topotecan increases topoisomerase II\u03b1 levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 57:1425\u20131428","journal-title":"Cancer Res"},{"key":"803_CR18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s002800050545","volume":"39","author":"JA Bonner","year":"1996","unstructured":"Bonner JA, Kozelsky TF (1996) The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 39:109\u2013112","journal-title":"Cancer Chemother Pharmacol"},{"key":"803_CR19","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/10428190600581385","volume":"47","author":"SM Smith","year":"2006","unstructured":"Smith SM, Johnson JL, Niedzwiecki D et al (2006) Sequential doxorubicin and topotecan in relapsed\/refractory aggressive NHL: results of CALGB 59906. Leuk Lymphoma 47:1511\u20131517","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"803_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/1097-0142(20010201)91:3<463::AID-CNCR1023>3.0.CO;2-R","volume":"91","author":"RR Kancherla","year":"2001","unstructured":"Kancherla RR, Nair JS, Ahmed T et al (2001) Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response. Cancer 91(3):463\u2013471","journal-title":"Cancer"},{"issue":"8","key":"803_CR21","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1080\/1042819021000002901","volume":"43","author":"M Crump","year":"2002","unstructured":"Crump M, Couban S, Meyer R et al (2002) Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin\u2019s lymphoma: a National Cancer Institute of Canada Clinical Trials Group Study. Leuk Lymphoma 43(8):1581\u20131587","journal-title":"Leuk Lymphoma"},{"key":"803_CR22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1023\/A:1011172215216","volume":"12","author":"A Younes","year":"2001","unstructured":"Younes A, Preti HA, Hagemeister FB et al (2001) Paxlitaxel plus topotecan for patients with relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol 12:923\u2013927","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0803-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0803-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:54Z","timestamp":1559023614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0803-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,23]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0803-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2008,7,23]]}}}